Testosterone Injections (TRT): Who They're For, Dosing, and Risks

The short version

Injectable testosterone replacement therapy (TRT) is a legitimate treatment for men with diagnosed hypogonadism, meaning consistent symptoms plus low testosterone confirmed on two separate morning blood draws, not low-normal levels or normal aging alone [1]. The two workhorse injectables, testosterone cypionate and enanthate, are dosed intramuscularly on a schedule, typically 50 to 400 mg every two to four weeks per the FDA label, and adjusted to lab results [2]. Done right, TRT can restore energy, libido, mood, and muscle in genuinely deficient men. Done casually, it carries real costs: it suppresses sperm production, can thicken the blood, and demands ongoing monitoring [3][4]. It is a medical relationship with labs and follow-up, not a one-click online purchase.

Who injectable TRT is actually for

TRT is indicated for men with clinically diagnosed hypogonadism, and the diagnostic bar matters. The Endocrine Society recommends making the diagnosis only in men who have both symptoms or signs of testosterone deficiency and unequivocally, consistently low serum testosterone [1]. Because testosterone is highest in the morning and fluctuates day to day, that means at least two low readings on separate early-morning fasting draws, not a single afternoon test.

This distinction rules out a large group of men who feel run down but do not have true hypogonadism. Fatigue, lower libido, and weight gain also come from poor sleep, depression, alcohol, thyroid disease, and untreated sleep apnea. A low-normal level in an aging man with no clear cause is not, by itself, a prescription for lifelong injections. The Endocrine Society specifically advises against routinely starting testosterone in all older men with low levels absent a distinct clinical picture [1]. The point of the workup is to confirm you are treating a real deficiency and to catch a reversible cause first.

The common injectable esters and how they are dosed

The two most-prescribed injectables in the United States are testosterone cypionate and testosterone enanthate. Both are testosterone attached to a fatty-acid ester that slows release from the injection site, so the hormone is absorbed over days rather than hours. They are close cousins with nearly interchangeable clinical behavior; cypionate is the more common US formulation. A longer-acting option, testosterone undecanoate, is dosed far less frequently but requires in-office administration because of a rare risk of pulmonary oil microembolism.

The FDA label for testosterone cypionate lists 50 to 400 mg intramuscularly every two to four weeks for replacement in hypogonadal men [2]. In practice many clinicians split the dose into smaller, more frequent injections (for example weekly) to smooth out the peaks and troughs, which can reduce swings in mood and energy. Some men self-inject at home after training; others receive injections in a clinic. The correct dose is not a fixed number. It is titrated to bring your levels into the mid-normal range and to how you feel and what your labs show, which is exactly why the drug cannot be dosed responsibly without follow-up testing [1].

What TRT can and cannot do

In men who are genuinely deficient, restoring testosterone reliably improves sexual desire and often erectile function, and tends to improve mood, energy, bone density, muscle mass, and body composition. These are meaningful gains, and they are the reason the treatment exists.

What TRT is not is a general-purpose vitality booster, an anti-aging protocol, or a fix for symptoms in men whose testosterone is normal. Benefits in men without clear deficiency are inconsistent, and giving supraphysiologic doses to chase performance moves you out of replacement and into anabolic-steroid territory, where the risk profile changes. Realistic expectations matter: TRT corrects a hormone deficit, it does not override the effects of poor sleep, inactivity, or an untreated mood disorder.

Fertility: TRT works against sperm production

This is the single most under-appreciated fact about injectable testosterone, especially for younger men. Exogenous testosterone suppresses the brain's signals (LH and FSH) that tell the testes to make their own testosterone and sperm. Intratesticular testosterone falls, and sperm production drops, often dramatically. The FDA label bluntly notes that oligospermia (low sperm count) may occur after prolonged administration [2].

The effect can be profound. A 2022 review reports that a large share of men become azoospermic (no measurable sperm) on testosterone [4]. The good news is that suppression is usually reversible after stopping: in pooled data cited in that review, roughly 67% of men recovered a sperm concentration of 20 million per milliliter by six months, about 90% by twelve months, and essentially all by twenty-four months [4]. But recovery timing varies widely and cannot be promised. Men who want children soon should raise fertility before starting. Alternatives that raise testosterone without shutting down the testes, or adding hCG, are worth discussing with a specialist first.

The real risks and the monitoring they require

Testosterone raises red-blood-cell production, and too much causes polycythemia (thickened blood), which can increase clot risk. The FDA label directs that hemoglobin and hematocrit be checked periodically during long-term therapy [2], and guidelines treat a hematocrit above 54% as a threshold to pause treatment or lower the dose [1]. The label also carries postmarketing reports of venous thromboembolic events, including deep vein thrombosis and pulmonary embolism [2].

On the heart, the large randomized TRAVERSE trial (5,246 men with hypogonadism and cardiovascular risk) found testosterone was noninferior to placebo for major adverse cardiac events, which was reassuring, but the testosterone group had more atrial fibrillation, pulmonary embolism, and acute kidney injury [3]. Prostate monitoring matters too: the label notes older men on androgens may face increased risk of prostatic hypertrophy and prostate cancer, so PSA and prostate assessment are part of follow-up [2]. Testosterone can also worsen untreated sleep apnea. None of this makes TRT unsafe for the right patient; it makes baseline and periodic labs non-negotiable.

Why it needs a real workup, not an online quick-start

Put the pieces together and the reason for caution is obvious. Diagnosis requires two confirmed low morning levels and a symptom picture [1]. Dosing has to be titrated to labs [2]. Ongoing safety depends on tracking hematocrit, PSA, and testosterone, plus a fertility conversation before you start [1][3][4]. A questionnaire and a single convenience blood draw cannot do that work.

A responsible program measures testosterone correctly, screens for reversible causes, checks a baseline hematocrit and PSA, sets a target range, and rechecks labs after starting and periodically thereafter. If a service is willing to ship testosterone based on symptoms alone, or skips repeat morning testing and follow-up bloodwork, that is a red flag, not convenience. Injectable testosterone is a genuinely useful medicine for men who need it, and a treatment that quietly costs fertility and blood-count safety for men who do not.